Targeting cancer cells with special nanoparticles for advanced ovarian cancer treatment
Cancer cell selective killing nanoparticle for advanced ovarian cancer treatment
This study is testing a new treatment made from tiny particles that can specifically target and kill ovarian cancer cells, especially those that don’t respond to regular therapies, with the hope of offering patients a safer and more effective option for managing their cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of South Carolina at Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10894936 on NIH RePORTER |
What this research studies
This research focuses on developing a novel polymer-metal nanoparticle that selectively kills ovarian cancer cells, particularly those that are resistant to traditional treatments. The approach involves understanding how these nanoparticles induce cell death specifically in cancer cells while sparing healthy cells, which is crucial for minimizing side effects. The research will explore the mechanisms of action, optimize the formulation for maximum effectiveness, and assess how the nanoparticles behave in the body, including their distribution and impact on tumor growth. Patients may benefit from a new, safer treatment option that could improve outcomes for advanced ovarian cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with advanced ovarian cancer, especially those who have not responded to conventional therapies.
Not a fit: Patients with early-stage ovarian cancer or those whose cancer is not resistant to standard treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking treatment option for patients with advanced ovarian cancer, particularly those with drug-resistant forms of the disease.
How similar studies have performed: While the approach of using nanoparticles for targeted cancer therapy is gaining traction, this specific method is novel and has not been extensively tested in prior studies.
Where this research is happening
Columbia, United States
- University of South Carolina at Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Xu, Peisheng — University of South Carolina at Columbia
- Study coordinator: Xu, Peisheng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.